Choksi Laboratories [CHOKSILA] vs Suraksha Diagnostic [SURAKSHA] Detailed Stock Comparison
Choksi Laboratories
BSE
Loading...
Suraksha Diagnostic
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Choksi Laboratories wins in 7 metrics, Suraksha Diagnostic wins in 11 metrics, with 0 ties. Suraksha Diagnostic appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Choksi Laboratories | Suraksha Diagnostic | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 84.11 | 46.74 | Suraksha Diagnostic |
| Price-to-Book Ratio | 5.32 | 7.38 | Choksi Laboratories |
| Debt-to-Equity Ratio | 123.52 | 42.28 | Suraksha Diagnostic |
| PEG Ratio | -10.09 | 2.58 | Choksi Laboratories |
| EV/EBITDA | 13.47 | 23.84 | Choksi Laboratories |
| Profit Margin (TTM) | 3.52% | 12.62% | Suraksha Diagnostic |
| Operating Margin (TTM) | 10.90% | 19.43% | Suraksha Diagnostic |
| EBITDA Margin (TTM) | 10.90% | 19.43% | Suraksha Diagnostic |
| Return on Equity | 6.45% | 15.14% | Suraksha Diagnostic |
| Return on Assets (TTM) | 2.33% | 9.54% | Suraksha Diagnostic |
| Free Cash Flow (TTM) | $40.91M | $213.35M | Suraksha Diagnostic |
| 1-Year Return | 156.84% | -27.68% | Choksi Laboratories |
| Price-to-Sales Ratio (TTM) | 2.96 | 5.91 | Choksi Laboratories |
| Enterprise Value | $1.55B | $16.26B | Suraksha Diagnostic |
| EV/Revenue Ratio | 3.66 | 6.17 | Choksi Laboratories |
| Gross Profit Margin (TTM) | 82.45% | 87.94% | Suraksha Diagnostic |
| Revenue per Share (TTM) | $61 | $51 | Choksi Laboratories |
| Earnings per Share (Diluted) | $2.14 | $6.40 | Suraksha Diagnostic |
| Beta (Stock Volatility) | 0.08 | N/A | N/A |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Choksi Laboratories vs Suraksha Diagnostic Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Choksi Laboratories | 4.25% | -8.02% | -20.17% | -3.34% | 56.24% | 95.99% |
| Suraksha Diagnostic | -2.02% | 1.11% | -0.76% | -6.58% | 12.85% | -20.61% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Choksi Laboratories | 156.84% | 352.69% | 1,519.72% | 1,273.93% | 908.86% | 301.25% |
| Suraksha Diagnostic | -27.68% | -27.68% | -27.68% | -27.68% | -27.68% | -27.68% |
News Based Sentiment: Choksi Laboratories vs Suraksha Diagnostic
Choksi Laboratories
News based Sentiment: MIXED
September presented a mixed bag for Choksi Laboratories, with a share price decline following the AGM offsetting positive long-term returns and a commitment to shareholder communication. The reduced trading volume suggests growing investor caution, making it a moderately significant month for investors.
Suraksha Diagnostic
News based Sentiment: POSITIVE
Suraksha Diagnostic Ltd. delivered strong Q1 FY26 results with significant revenue and profit growth, and is strategically expanding into the high-growth genomics market. These developments suggest a positive trajectory for the company, making it a noteworthy investment story for the month.
Performance & Financial Health Analysis: Choksi Laboratories vs Suraksha Diagnostic
| Metric | CHOKSILA | SURAKSHA |
|---|---|---|
| Market Information | ||
| Market Cap | ₹1.26B | ₹15.72B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 8,255 | 56,969 |
| 90 Day Avg. Volume | 7,354 | 47,590 |
| Last Close | ₹184.05 | ₹295.65 |
| 52 Week Range | ₹60.21 - ₹236.70 | ₹231.00 - ₹449.00 |
| % from 52W High | -22.24% | -34.15% |
| All-Time High | ₹236.70 (Aug 20, 2025) | ₹449.00 (Dec 02, 2024) |
| % from All-Time High | -22.24% | -34.15% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.05% | 0.21% |
| Quarterly Earnings Growth | -0.09% | 0.18% |
| Financial Health | ||
| Profit Margin (TTM) | 0.04% | 0.13% |
| Operating Margin (TTM) | 0.11% | 0.19% |
| Return on Equity (TTM) | 0.06% | 0.15% |
| Debt to Equity (MRQ) | 123.52 | 42.28 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹33.82 | ₹40.56 |
| Cash per Share (MRQ) | ₹0.88 | ₹3.86 |
| Operating Cash Flow (TTM) | ₹51.38M | ₹365.13M |
| Levered Free Cash Flow (TTM) | ₹15.23M | ₹318.24M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Choksi Laboratories vs Suraksha Diagnostic
| Metric | CHOKSILA | SURAKSHA |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 84.11 | 46.74 |
| Forward P/E | N/A | 32.27 |
| PEG Ratio | -10.09 | 2.58 |
| Price to Sales (TTM) | 2.96 | 5.91 |
| Price to Book (MRQ) | 5.32 | 7.38 |
| Market Capitalization | ||
| Market Capitalization | ₹1.26B | ₹15.72B |
| Enterprise Value | ₹1.55B | ₹16.26B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 3.66 | 6.17 |
| Enterprise to EBITDA | 13.47 | 23.84 |
| Risk & Other Metrics | ||
| Beta | 0.08 | N/A |
| Book Value per Share (MRQ) | ₹33.82 | ₹40.56 |
Financial Statements Comparison: Choksi Laboratories vs Suraksha Diagnostic
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | CHOKSILA | SURAKSHA |
|---|---|---|
| Revenue/Sales | ₹112.42M | ₹725.86M |
| Cost of Goods Sold | ₹19.73M | ₹87.51M |
| Gross Profit | ₹92.69M | ₹638.36M |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹12.28M | ₹133.78M |
| EBITDA | ₹29.04M | ₹237.66M |
| Pre-Tax Income | ₹6.27M | ₹124.69M |
| Income Tax | ₹2.42M | ₹32.94M |
| Net Income (Profit) | ₹3.85M | ₹91.75M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | CHOKSILA | SURAKSHA |
|---|---|---|
| Cash & Equivalents | ₹6.12M | ₹22.47M |
| Total Current Assets | ₹163.21M | ₹471.53M |
| Total Current Liabilities | ₹238.75M | ₹427.17M |
| Long-Term Debt | ₹159.63M | ₹741.03M |
| Total Shareholders Equity | ₹236.05M | ₹2.10B |
| Retained Earnings | ₹150.56M | ₹1.54B |
| Property, Plant & Equipment | ₹471.35M | ₹1.38B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | CHOKSILA | SURAKSHA |
|---|---|---|
| Operating Cash Flow | N/A | ₹148.52M |
| Capital Expenditures | N/A | ₹-123.19M |
| Free Cash Flow | N/A | ₹64.63M |
| Debt Repayment | N/A | ₹-7.29M |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | CHOKSILA | SURAKSHA |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 8,255 | 56,969 |
| Average Daily Volume (90 Day) | 7,354 | 47,590 |
| Shares Outstanding | 6.97M | 52.08M |
| Float Shares | 3.47M | 21.51M |
| % Held by Insiders | 0.59% | 0.62% |
| % Held by Institutions | 0.00% | 0.23% |
Dividend Analysis & Yield Comparison: Choksi Laboratories vs Suraksha Diagnostic
| Metric | CHOKSILA | SURAKSHA |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |